2001 CordLife Pte Ltd established and licensed by Ministry of Health (MOH) Singapore 2002 First cord blood released for sibling-use. Laboratory at Camden Medical Centre opened for public viewing. 2005 Received accreditation from American Association of Blood Banks (AABB) AABB's Accreditation Program strives to improve the quality and safety of collecting, processing, testing, distributing and administering blood and blood products by assessing the quality and operational systems in place within the facility. Offered Medicord, a stem cell transplant insurance programme. Entered Hong Kong and People's Republic of China (PRC) markets. 2007 Expanded to new Science Park II facility. Cordlife Hong Kong achieved ISO:9001. 2008 Re-accredited by American Association of Blood Banks (AABB). Launch of automated processing system to maximise recovery of cells for transplant use 2009 Re-accredited by American Association of Blood Banks (AABB). First-ever release of autologous cord blood for Cerebral Palsy Launched Cordlife Quality Guarantee, a warranty to protect Cordlife clients. Launched Cordlife Circle, a members-only benefit programme. Launched Preferential Plan upgrades for clients. 2010 First-ever release of autologous cord blood for Neuroblastoma. Released autologous cord blood for Cerebral Palsy. Celebrated enrolment of our 25,000th client. Celebrated 10 years of quality cord blood banking. 2011 CordLife Pte Ltd renamed to "Cordlife Group Limited". Launched Cordlife Care360° Safeguard programme. Re-accredited by American Association of Blood Banks (AABB). Launched provision of umbilical cord tissue banking services in Hong Kong. Hong Kong facility accredited by American Association of Blood Banks (AABB) 2012 Successfully listed on Singapore Exchange Main Board on 29 March 2012. More than 40,000 clients stored their precious stem cells with Cordlife. 2013 Cordlife Group Limited moved to its fully owned, 23,000sqft office and laboratory facility in A'Posh Bizhub, Yishun. The facility is capable of storing up to 650,000 cord blood units. First private cord blood bank in Singapore to launch automated processing system to facilitate the optimisation of cord blood stem cells for maximum transplant success*. Re-accredited by American Association of Blood Banks (AABB). Launched provision of umbilical cord lining banking services in Singapore with patented technology, CellOptima™ that is exclusively available at Cordlife capable of isolating EpSCs and MSCs, two types of stem cells present in the umbilical cord. Awarded 'Most Transparent Company Award' by SIAS Investors Choice 2014 Processed and stored over 45,000 cord blood units as of 21 March 2014. Collaborated with Make-A-Wish Foundation® (Singapore) Ltd granting the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy. Enhanced Cordlife Pledge:360° assures quality processing and storage standards 2015 Received accreditation from FACT which ensures the global standard of excellence in patient care and laboratory practices. Cordlife is one out of the six private cord blood banks worldwide that is double-accredited and the first in Southeast Asia to achieve the dual-accreditation status with AABB and FACT (The Foundation for the Accreditation of Cellular Therapy). Launched the Cordlife-Jalan Kayu Pre-School Headstart Fund with a sponsorship of $150K to give young children from low-income families a chance in pre-school education. Partnered with autism and epilepsy treatment pioneer, Dr Michael Chez from Sutter Medical Group and Sutter Neuroscience Institute in the continued study of autologous cord blood cells treatments. Received the 16th SIAS Investors Choice Award (Runnerup), Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category. Honoured by Forbes Asia as one of the "Best Under a Billion" companies in November 2015. Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries. *Conditions apply.
